Evidence map›Paper›PMID 38287373›Full record

ArticleChinese medicine2024

Gromwell ameliorates glucocorticoid-induced muscle atrophy through the regulation of Akt/mTOR pathway.

Ahyoung Yoo, Jung-In Kim, Hyunjung Lee, Farida S Nirmala, Jeong-Hoon Hahm, Hyo Deok Seo, Chang Hwa Jung, Tae Youl Ha, Jiyun Ahn

Open access · goldAbstract read
In one paragraph

Article in Chinese medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Gromwell (Food science and biotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ahyoung YooAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Jung-In KimAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Hyunjung LeeAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Farida S NirmalaAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Jeong-Hoon HahmAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Hyo Deok SeoAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Chang Hwa JungAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Tae Youl HaAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Jiyun AhnAging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea. jyan@kfri.re.kr.
Korea Food Research Institute · KRKorea University of Science and Technology · KR

Funding

Korea Food Research Institute E0210100Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, and Forestry 821059
6 · The paper itself

Abstract

backgroundMuscle atrophy is characterized by decreased muscle mass, function, and strength. Synthetic glucocorticoids, including dexamethasone (Dexa), are commonly used to treat autoimmune diseases. However, prolonged exposure of Dexa with high dose exerts severe side effects, including muscle atrophy. The purpose of this study was to investigate whether Gromwell root extract (GW) can prevent Dexa-induced muscle atrophy in C2C12 cells and mice and to characterize the composition of GW to identify bioactive compounds.

methodsFor in vitro experiments, GW (0.5 and 1 µg/mL) or lithospermic acid (LA, 5 and 10 µM) was added to C2C12 myotubes on day 4 of differentiation and incubated for 24 h, along with 50 µM Dexa. For in vivo experiment, four-week-old male C57BL/6 mice were randomly divided into the four following groups (n = 7/group): Con group, Dexa group, GW0.1 group, and GW0.2 group. Mice were fed experimental diets of AIN-93 M with or without 0.1 or 0.2% GW for 4 weeks. Subsequently, muscle atrophy was induced by administering an intraperitoneal injection of Dexa at a dose of 15 mg/kg/day for 38 days, in conjunction with dietary intake.

resultsIn Dexa-induced myotube atrophy, treatment with GW increased myotube diameter, reduced the expression of muscle atrophy markers, and enhanced the expression of myosin heavy chain (MHC) isoforms in C2C12 cells. Supplementation with the GW improved muscle function and performance in mice with Dexa-induced muscle atrophy, evidenced in the grip strength and running tests. The GW group showed increased lean body mass, skeletal muscle mass, size, and myosin heavy chain isoform expression, along with reduced skeletal muscle atrophy markers in Dexa-injected mice. Supplementation with GW increased protein synthesis and decreased protein degradation through the Akt/mammalian target of rapamycin and glucocorticoid receptor/forkhead box O3 signaling pathways, respectively. We identified LA as a potential bioactive component of the GW. LA treatment increased myotube diameter and decreased the expression of muscle atrophy markers in Dexa-induced C2C12 cells.

conclusionsThese findings underscore the potential of the GW in preventing Dexa-induced skeletal muscle atrophy and highlight the contribution of LA to its effects.

Indexed as

DexamethasoneGromwellLithospermic acidLithospermum erythrorhizonmTOR/glucocorticoid receptorMuscle atrophy

Identifiers

PMID38287373
PMCPMC10826094
OpenAlexW4391323308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.